<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884272</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-126</org_study_id>
    <nct_id>NCT01884272</nct_id>
  </id_info>
  <brief_title>NSAID Drug Interaction Study</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Potential Two-Way Pharmacokinetic Interaction Between Lesinurad and Naproxen and Between Lesinurad and Indomethacin in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug-drug interaction study in healthy volunteers to evaluate the potential
      pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and
      leinurad on the non-steroidal anti-inflammatory drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naproxen and indomethacin are non-steroidal anti-inflammatory drugs (NSAIDs) used both
      prophylactically for the prevention of, and as a treatment for, acute gout flares.
      RDEA594-126 is an open-label study designed to assess the potential effect of multiple doses
      of naproxen and indomethacin on the single-dose PK of lesinurad, and to assess the potential
      effect of multiple doses of lesinurad on the multiple-dose PK of naproxen and indomethacin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of lesinurad from plasma and urine</measure>
    <time_frame>Day 1, Day 6 (urine only), Day 7, Day 14</time_frame>
    <description>Profile in terms of AUC, Tmax, Cmax, and t1/2 AUC: area under the plasma concentration versus time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK profile of naproxen and indomethacin from plasma and urine</measure>
    <time_frame>Day 1, Day 6 (urine only), Day 7, Day 14</time_frame>
    <description>Profile in terms of AUC, Tmax, Cmax, and t1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Lesinurad 400 mg and naproxen 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lesinurad 400 mg and indomethacin 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesinurad 400 mg</intervention_name>
    <arm_group_label>Lesinurad 400 mg and naproxen 250 mg</arm_group_label>
    <arm_group_label>Lesinurad 400 mg and indomethacin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen 250 mg</intervention_name>
    <arm_group_label>Lesinurad 400 mg and naproxen 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indomethacin 25 mg</intervention_name>
    <arm_group_label>Lesinurad 400 mg and indomethacin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body weight ≥ 50 kg (110 lbs) and a body mass index (BMI) ≥ 18 and ≤ 30
             kg/m2.

          -  Subject is free of any clinically significant disease that requires a physician's care
             and/or would interfere with study evaluations or procedures.

          -  Subject has no clinically relevant abnormalities in vital signs, ECG, physical
             examination or safety laboratory values.

        Exclusion Criteria:

          -  Subject has clinically significant pulmonary, cardiovascular, gastrointestinal,
             neurologic, hepatic, renal, urological, or psychiatric disorders.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has a history of asthma.

          -  Subject has undergone major surgery within 3 months prior to Day 1.

          -  Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12
             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening
             visit.

          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Bradley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

